| Characteristic . | Patients (n = 213), n (%) . |
|---|---|
| Median age, yr | 59 |
| Gender, female | 125 (59) |
| Race/ethnicity | |
| Non-Hispanic White | 153 (72) |
| Hispanic | 27 (13) |
| Black | 18 (8) |
| Asian | 6 (3) |
| Other | 4 (2) |
| No response | 5 (2) |
| Type of cancera | |
| Brain | 5 (2) |
| Breast | 20 (9) |
| Cervical | 7 (3) |
| Colorectal | 27 (13) |
| Head and neck | 16 (8) |
| Liver | 11 (5) |
| Kidney | 9 (4) |
| Lung | 27 (13) |
| Melanoma | 10 (5) |
| Ovarian | 20 (9) |
| Pancreatic | 9 (4) |
| Prostate | 10 (5) |
| Sarcoma | 17 (8) |
| Thyroid | 18 (8) |
| Other | 39 (18) |
| Yearly household income | |
| <$30,000 | 40 (19) |
| $30,001–$60,000 | 53 (25) |
| $60,001–$100,000 | 64 (30) |
| $100,001–$200,000 | 35 (16) |
| $200,001–$400,000 | 11 (5) |
| >$600,000 | 3 (1) |
| No response | 7 (3) |
| Current employment status | |
| Unemployed | 32 (15) |
| Employed, on medical leave | 12 (6) |
| Employed, part time | 13 (6) |
| Employed, full time | 59 (28) |
| Retired | 78 (37) |
| Not working outside the home | 19 (9) |
| Insurance typea | |
| Medicare | 79 (37) |
| Employer-provided | 114 (54) |
| Medicaid | 5 (2) |
| Personally purchased | 23 (11) |
| VA | 8 (4) |
| Personally purchased supplemental | 18 (8) |
| Other | 3 (1) |
| No response | 5 (2) |
| Length of time in current trial | |
| <1 month | 5 (2) |
| 1 month–2 months | 87 (41) |
| 3 month–4 months | 39 (18) |
| 5 months–6 months | 20 (9) |
| >6 months | 60 (28) |
| Unknown | 2 (1) |
| Form of anticancer medications for current trial | |
| Pills, capsules, or tablets taken by mouth | 77 (36) |
| Intravenous infusion | 91 (43) |
| Both | 42 (20) |
| Unknown | 3 (1) |
| Prior phase I clinical trials | |
| 0 | 134 (63) |
| 1 | 39 (18) |
| 2 | 25 (12) |
| ≥3 | 14 (7) |
| Unknown | 1 (0) |
| Characteristic . | Patients (n = 213), n (%) . |
|---|---|
| Median age, yr | 59 |
| Gender, female | 125 (59) |
| Race/ethnicity | |
| Non-Hispanic White | 153 (72) |
| Hispanic | 27 (13) |
| Black | 18 (8) |
| Asian | 6 (3) |
| Other | 4 (2) |
| No response | 5 (2) |
| Type of cancera | |
| Brain | 5 (2) |
| Breast | 20 (9) |
| Cervical | 7 (3) |
| Colorectal | 27 (13) |
| Head and neck | 16 (8) |
| Liver | 11 (5) |
| Kidney | 9 (4) |
| Lung | 27 (13) |
| Melanoma | 10 (5) |
| Ovarian | 20 (9) |
| Pancreatic | 9 (4) |
| Prostate | 10 (5) |
| Sarcoma | 17 (8) |
| Thyroid | 18 (8) |
| Other | 39 (18) |
| Yearly household income | |
| <$30,000 | 40 (19) |
| $30,001–$60,000 | 53 (25) |
| $60,001–$100,000 | 64 (30) |
| $100,001–$200,000 | 35 (16) |
| $200,001–$400,000 | 11 (5) |
| >$600,000 | 3 (1) |
| No response | 7 (3) |
| Current employment status | |
| Unemployed | 32 (15) |
| Employed, on medical leave | 12 (6) |
| Employed, part time | 13 (6) |
| Employed, full time | 59 (28) |
| Retired | 78 (37) |
| Not working outside the home | 19 (9) |
| Insurance typea | |
| Medicare | 79 (37) |
| Employer-provided | 114 (54) |
| Medicaid | 5 (2) |
| Personally purchased | 23 (11) |
| VA | 8 (4) |
| Personally purchased supplemental | 18 (8) |
| Other | 3 (1) |
| No response | 5 (2) |
| Length of time in current trial | |
| <1 month | 5 (2) |
| 1 month–2 months | 87 (41) |
| 3 month–4 months | 39 (18) |
| 5 months–6 months | 20 (9) |
| >6 months | 60 (28) |
| Unknown | 2 (1) |
| Form of anticancer medications for current trial | |
| Pills, capsules, or tablets taken by mouth | 77 (36) |
| Intravenous infusion | 91 (43) |
| Both | 42 (20) |
| Unknown | 3 (1) |
| Prior phase I clinical trials | |
| 0 | 134 (63) |
| 1 | 39 (18) |
| 2 | 25 (12) |
| ≥3 | 14 (7) |
| Unknown | 1 (0) |
aSome patients selected more than one option, so numbers add up to greater than 100%.
Abbreviation: VA, Veterans Administration.
| Characteristic . | Patients (n = 213), n (%) . |
|---|---|
| Median age, yr | 59 |
| Gender, female | 125 (59) |
| Race/ethnicity | |
| Non-Hispanic White | 153 (72) |
| Hispanic | 27 (13) |
| Black | 18 (8) |
| Asian | 6 (3) |
| Other | 4 (2) |
| No response | 5 (2) |
| Type of cancera | |
| Brain | 5 (2) |
| Breast | 20 (9) |
| Cervical | 7 (3) |
| Colorectal | 27 (13) |
| Head and neck | 16 (8) |
| Liver | 11 (5) |
| Kidney | 9 (4) |
| Lung | 27 (13) |
| Melanoma | 10 (5) |
| Ovarian | 20 (9) |
| Pancreatic | 9 (4) |
| Prostate | 10 (5) |
| Sarcoma | 17 (8) |
| Thyroid | 18 (8) |
| Other | 39 (18) |
| Yearly household income | |
| <$30,000 | 40 (19) |
| $30,001–$60,000 | 53 (25) |
| $60,001–$100,000 | 64 (30) |
| $100,001–$200,000 | 35 (16) |
| $200,001–$400,000 | 11 (5) |
| >$600,000 | 3 (1) |
| No response | 7 (3) |
| Current employment status | |
| Unemployed | 32 (15) |
| Employed, on medical leave | 12 (6) |
| Employed, part time | 13 (6) |
| Employed, full time | 59 (28) |
| Retired | 78 (37) |
| Not working outside the home | 19 (9) |
| Insurance typea | |
| Medicare | 79 (37) |
| Employer-provided | 114 (54) |
| Medicaid | 5 (2) |
| Personally purchased | 23 (11) |
| VA | 8 (4) |
| Personally purchased supplemental | 18 (8) |
| Other | 3 (1) |
| No response | 5 (2) |
| Length of time in current trial | |
| <1 month | 5 (2) |
| 1 month–2 months | 87 (41) |
| 3 month–4 months | 39 (18) |
| 5 months–6 months | 20 (9) |
| >6 months | 60 (28) |
| Unknown | 2 (1) |
| Form of anticancer medications for current trial | |
| Pills, capsules, or tablets taken by mouth | 77 (36) |
| Intravenous infusion | 91 (43) |
| Both | 42 (20) |
| Unknown | 3 (1) |
| Prior phase I clinical trials | |
| 0 | 134 (63) |
| 1 | 39 (18) |
| 2 | 25 (12) |
| ≥3 | 14 (7) |
| Unknown | 1 (0) |
| Characteristic . | Patients (n = 213), n (%) . |
|---|---|
| Median age, yr | 59 |
| Gender, female | 125 (59) |
| Race/ethnicity | |
| Non-Hispanic White | 153 (72) |
| Hispanic | 27 (13) |
| Black | 18 (8) |
| Asian | 6 (3) |
| Other | 4 (2) |
| No response | 5 (2) |
| Type of cancera | |
| Brain | 5 (2) |
| Breast | 20 (9) |
| Cervical | 7 (3) |
| Colorectal | 27 (13) |
| Head and neck | 16 (8) |
| Liver | 11 (5) |
| Kidney | 9 (4) |
| Lung | 27 (13) |
| Melanoma | 10 (5) |
| Ovarian | 20 (9) |
| Pancreatic | 9 (4) |
| Prostate | 10 (5) |
| Sarcoma | 17 (8) |
| Thyroid | 18 (8) |
| Other | 39 (18) |
| Yearly household income | |
| <$30,000 | 40 (19) |
| $30,001–$60,000 | 53 (25) |
| $60,001–$100,000 | 64 (30) |
| $100,001–$200,000 | 35 (16) |
| $200,001–$400,000 | 11 (5) |
| >$600,000 | 3 (1) |
| No response | 7 (3) |
| Current employment status | |
| Unemployed | 32 (15) |
| Employed, on medical leave | 12 (6) |
| Employed, part time | 13 (6) |
| Employed, full time | 59 (28) |
| Retired | 78 (37) |
| Not working outside the home | 19 (9) |
| Insurance typea | |
| Medicare | 79 (37) |
| Employer-provided | 114 (54) |
| Medicaid | 5 (2) |
| Personally purchased | 23 (11) |
| VA | 8 (4) |
| Personally purchased supplemental | 18 (8) |
| Other | 3 (1) |
| No response | 5 (2) |
| Length of time in current trial | |
| <1 month | 5 (2) |
| 1 month–2 months | 87 (41) |
| 3 month–4 months | 39 (18) |
| 5 months–6 months | 20 (9) |
| >6 months | 60 (28) |
| Unknown | 2 (1) |
| Form of anticancer medications for current trial | |
| Pills, capsules, or tablets taken by mouth | 77 (36) |
| Intravenous infusion | 91 (43) |
| Both | 42 (20) |
| Unknown | 3 (1) |
| Prior phase I clinical trials | |
| 0 | 134 (63) |
| 1 | 39 (18) |
| 2 | 25 (12) |
| ≥3 | 14 (7) |
| Unknown | 1 (0) |
aSome patients selected more than one option, so numbers add up to greater than 100%.
Abbreviation: VA, Veterans Administration.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
